Holen Sie sich die Stockscreener-App
2.05
5.67%
0.11
Handel nachbörslich:
2.06
0.01
+0.49%
Schlusskurs vom Vortag:
$1.94
Offen:
$2
24-Stunden-Volumen:
1.38M
Relative Volume:
0.82
Marktkapitalisierung:
$148.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.96M
KGV:
-0.6212
EPS:
-3.3
Netto-Cashflow:
$-167.04M
1W Leistung:
-11.26%
1M Leistung:
-8.07%
6M Leistung:
-10.87%
1J Leistung:
-4.21%
1-Tages-Spanne:
$1.96
$2.13
1-Wochen-Bereich:
$1.91
$2.30
52-Wochen-Spanne:
$1.67
$11.48
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Firmenname
Ventyx Biosciences Inc
Sektor
Branche
Telefon
(858) 945-2393
Adresse
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Vergleichen Sie VTYX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
2.05 | 148.85M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-03-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-11-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-19 | Eingeleitet | Goldman | Buy |
| 2022-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-07 | Eingeleitet | Stifel | Buy |
| 2022-09-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-09 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-02-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-15 | Eingeleitet | Jefferies | Buy |
| 2021-11-15 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) high institutional ownership speaks for itself as stock continues to impress, up 10% over last week - Simply Wall St
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Acquired by Barclays PLC - Defense World
JPMorgan Chase & Co. Has $2.20 Million Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
What is HC Wainwright’s Estimate for VTYX FY2024 Earnings? - Defense World
HC Wainwright Analysts Increase Earnings Estimates for VTYX - MarketBeat
FY2029 Earnings Estimate for VTYX Issued By HC Wainwright - Defense World
Research Analysts Set Expectations for VTYX FY2029 Earnings - MarketBeat
Ventyx Biosciences Discloses Preliminary 2024 Financials and Pipeline Strategy - Defense World
Ventyx Biosciences highlights its 2025 pipeline strategy - Yahoo Finance
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Jane Street Group LLC - Defense World
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio - GlobeNewswire
Ventyx Biosciences advances NLRP3 inhibitor trials By Investing.com - Investing.com Canada
HC Wainwright Reaffirms Neutral Rating for Ventyx Biosciences (NASDAQ:VTYX) - MarketBeat
Ventyx Biosciences highlights 2025 pipeline strategy and provides clinical updates; shares rise - MSN
Ventyx Biosciences Unveils 2025 Pipeline and Clinical Updates - TipRanks
Ventyx Biosciences advances NLRP3 inhibitor trials - Investing.com
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on Its Nlrp3 Inhibitor Portfolio - Marketscreener.com
Ventyx Biosciences Inc’s (VTYX) -10.71% Retreat Justifies A Second Look - Stocks Register
We're Keeping An Eye On Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate - Yahoo Finance
Barclays PLC Increases Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Geode Capital Management LLC Has $3.03 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
State Street Corp Acquires 9,783 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences chief scientific officer sells $49,840 in stock By Investing.com - Investing.com Australia
Ventyx Biosciences chief scientific officer sells $49,840 in stock - Investing.com India
John Nuss Sells 21,119 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock - MarketBeat
Ventyx Biosciences director Sheila Gujrathi buys $300,573 in stock - Investing.com India
Sheila Gujrathi Buys 130,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock - MarketBeat
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider John Nuss Sells 13,161 Shares - MarketBeat
Ventyx Biosciences' chief scientific officer sells $29,682 in stock - Investing.com
Ventyx Biosciences' chief scientific officer sells $29,682 in stock By Investing.com - Investing.com UK
Insiders Enjoy US$190k Return After Buying Ventyx Biosciences Stock - Simply Wall St
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k - Yahoo Finance
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Cryopyrin-associated Periodic Syndromes Market on Track for Major Expansion by 2034, According to DelveInsight | Amgen, Biovitrum, Novartis, Ventyx Biosciences - The Globe and Mail
Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Bought by Vestal Point Capital LP - MarketBeat
Sio Capital Management LLC Raises Stock Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat
Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Whitney Tilson, Steven Cohen, Scott Bessent, Millennium Management, Paloma Partners, Ventyx Biosciences Inc (VTYX), Vistra Corp (VST), and More - Insider Monkey
Ventyx Biosciences Inc (NASDAQ: VTYX) Jumps 11.35%, Turning Investors Away - Stocks Register
Ventyx Biosciences CEO Mohan Raju buys $959,889 in stock By Investing.com - Investing.com Nigeria
Ventyx Biosciences CEO Mohan Raju buys $959,889 in stock - Investing.com
Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Price Target at $10.00 - MarketBeat
Finanzdaten der Ventyx Biosciences Inc-Aktie (VTYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):